Landmark Series: Immunotherapy and Targeted Therapy for Pancreatic Cancer

Research output: Contribution to journalArticlepeer-review

10 Scopus citations


Pancreatic cancer is one of the most aggressive gastrointestinal malignancies despite multimodality therapy. In the last several years, genomic studies have revealed that carcinogenesis is driven largely by key driver mutations that can be targeted for oncologic therapy. In addition, advances in cancer immunology have identified receptors and monoclonal antibodies that can be manipulated into harnessing the power of the host’s immune system for antitumor treatment. These strategies have generated a paradigm shift in the management of several cancer types, including those in the gastrointestinal tract. However, there are several complicating factors when translating the results to pancreatic cancer, including the dense, fibrotic stroma unique to this disease that may shield the cancer cells from both cytotoxic and immunologic agents. Although the majority of trials have been performed in the metastatic setting, this review will focus on both the historic studies that have defined this field as well as the emerging data arising from ongoing efforts to exploit newly discovered mutations and their druggable targets.

Original languageEnglish (US)
Pages (from-to)1400-1406
Number of pages7
JournalAnnals of surgical oncology
Issue number3
StatePublished - Mar 2021


  • Immunotherapy
  • Neoadjuvant therapy
  • Pancreatic cancer
  • Targeted therapy

ASJC Scopus subject areas

  • Surgery
  • Oncology


Dive into the research topics of 'Landmark Series: Immunotherapy and Targeted Therapy for Pancreatic Cancer'. Together they form a unique fingerprint.

Cite this